Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

NCT02062073 | Completed Phase 1

• 1 other identifier: Ha03-006
• Study Type: interventional
• Target: 238
• Locations: 1 country
• Sites: 1

Brief Summary

Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.

Conditions

Head Lice

Keywords

head lice; Hatchtech

Outcome Measures

Primary Outcomes (1)

• to evaluate the sensitizing potential of abametapir lotion using repeat insult patch test design

  Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation

  8 weeks

Study Arms (4)

Abametapir Lotion 0.74%

ACTIVE COMPARATOR

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Drug: Abametapir Lotion 0.74% w/w

Vehicle Lotion

PLACEBO COMPARATOR

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Other: Vehicle Lotion

0.1% sodium lauryl sulfate

OTHER

Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Other: 0.1% sodium lauryl sulfate

Saline 0.9%

OTHER

Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Other: saline 0.9%

Interventions

Abametapir Lotion 0.74% w/w DRUG

Abametapir Lotion 0.74%

0.1% sodium lauryl sulfate OTHER

0.1% sodium lauryl sulfate

saline 0.9% OTHER

Saline 0.9%

Vehicle Lotion OTHER

Vehicle Lotion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Are healthy (to be confirmed by medical history) males or females, 18 years of age or older;
• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
• If female of childbearing potential, have a negative urine pregnancy test at Day 1, and are willing to submit to a pregnancy test at the end of study;
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
• Complete a patch study Medical Screening form as well as a Medical Personal History form; and
• Read, understand, and provide signed informed consent.

You may not qualify if:

• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
• Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
• Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
• Have psoriasis and/or active atopic dermatitis/eczema;
• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
• Have a known sensitivity to constituents present in the material being evaluated;
• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
• Have received treatment for any type of internal cancer within 5 years prior to study entry;
• Have a history of, or are currently being treated for skin cancer;
• Are currently participating in any other clinical trial;
• Have any known sensitivity to adhesives; and/or
• Have received any investigational treatment(s) within 4 weeks prior to study entry.

Sponsors & Collaborators

• Dr. Reddy's Laboratories Limited: lead
• TKL Research, Inc.: collaborator
• Accelovance: collaborator

Study Sites (1)

TKL Reserach

Paramus, New Jersey, 07652, United States

Location

MeSH Terms

Interventions

Sodium Dodecyl Sulfate; Sodium Chloride

Intervention Hierarchy (Ancestors)

Dodecanol; Fatty Alcohols; Alcohols; Organic Chemicals; Alkanesulfonates; Alkanesulfonic Acids; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Lipids; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• Jonathan Dosik

  TKL Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2014
• First Posted: February 13, 2014
• Study Start: January 1, 2014
• Primary Completion: March 1, 2014
• Study Completion: June 1, 2014
• Last Updated: April 29, 2020

Record last verified: 2020-04

Locations

US (1)